New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis

Phase 3positiveEBGLYSSPositive

AI Analysis

Summary

Eli Lilly announced positive Phase 3b data for EBGLYSS (lebrikizumab-lbkz) in moderate-to-severe hand and foot atopic dermatitis, with the drug meeting its primary endpoint by achieving clear or almost clear skin in over 50% of patients at Week 16 and demonstrating significant itch and pain relief.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Met primary endpoint with >50% of patients achieving HF-IGA 0/1 (clear or almost clear skin) by Week 16; significant improvements in itch and pain relief

Importance:7/10

Sentiment:

0.85

Phase 3bPositive dataAtopic dermatitisDermatologyMonotherapy

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on September 30, 2026 12:03 PM

Read Original